OGT SureSeq Myeloid MRD Plus NGS Panel

OGT has launched its next-generation sequencing (NGS) panel for measurable residual disease (MRD): the SureSeq Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of expertise in hybrid capture technology, the panel detects ultralow-frequency variants in key MRD-associated biomarkers in acute myeloid leukaemia (AML). This means users can obtain detailed genomic information, to provide an earlier and more complete picture of their sample’s MRD status.

Detection of MRD is a pivotal component in advancing clinical research and improving our understanding of therapeutic strategies for AML. Evidence consistently demonstrates that MRD-negative status is associated with significantly improved long-term outcomes and the ability to sensitively identify even a small number of residual leukemic cells at earlier time points. This provides clinicians and researchers with a more detailed snapshot of disease status.

With targeted coverage of 16 biomarkers associated with AML, including FLT3 and NPM1, the panel is optimised for MRD characterisation. Users benefit from robust detection of complex and challenging mutations such as FLT3 internal tandem duplications (ITDs) exceeding 300 base pairs, so they can obtain comprehensive genomic insights from their samples. Additionally, its focused design enables high-precision variant detection without the increased sequencing costs typically associated with broader panels and, by leveraging SureSeq’s refined bait design strategy, the panel achieves high sensitivity, detecting variants at allele frequencies as low as 0.01%.

Complementing the panel is Interpret, OGT’s powerful bioinformatics solution provided at no additional cost, which includes longitudinal visualisation of MRD dynamics over time — including SNVs, indels and ITDs. Available as a secure cloud-based platform or local installation, it offers user-friendly preconfigured analysis pipelines which streamline laboratory workflows and accelerate implementation. Additionally, customisation options allow users to tailor their analysis to meet their specific clinical research needs.

The panel and bioinformatics solution are supported by OGT’s dedicated team of experts, who provide comprehensive assistance from initial set-up through to advanced troubleshooting, enabling seamless adoption of MRD detection.